CTI BioPharma (CTIC) Granted FDA Accelerated Approval of VONJO
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/7/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
CTI BioPharma (CTIC) PT Raised to $12 at Brookline Capital Markets Following FDA Approval
March 1, 2022 10:13 AM ESTBrookline Capital Markets analyst Leah Rush Cann raised the price target on CTI BioPharma (NASDAQ: CTIC) to $12.00 (from $7.20) while maintaining a Buy rating following FDA approval for Pacritinib (Vonjo) in Myelofibrosis.
The analyst commented, "The timing of this FDA-approval is as expected and the prescribing label, with no black box warning and an... More
CTI BioPharma (CTIC) Climbs 37% Following Accelerated FDA Approval of VONJO
March 1, 2022 7:17 AM ESTCTI BioPharma (NASDAQ: CTIC) Climbs 37% Following Accelerated FDA Approval of VONJO
... More